What This Means for Dihexa Users Today The failure of fosgonimeton in Alzheimer's trials establishes an important fact: a compound that showed promise in animal models and early human studies did not slow cognitive decline in Alzheimer's patients
Available from: Gounden V, Bhatt H, Jialal I
Patients should contact their healthcare provider if they experience excessive thirst (polydipsia) that persists despite adequate fluid intake, as this may signal uncontrolled diabetes or other metabolic disturbances
Financing or payment-plan options may be availablecheck with the clinic
IV NAD therapies are not FDA-approved , have no standardized dosing, and may cause nausea, flushing, anxiety, or tachycardia
Gastric Emptying Inhibition and Postprandial Glycemic Control: Investigating the modulation of upper gastrointestinal motility